drugset / Trial / NCT01780519

The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms

NCT01780519

Phase 1 Completed 57 enrolled Mayo Clinic
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The investigators' goal is to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam, can predict whether or not an individual is at risk for developing Alzheimer's disease.

Timeline

Start
2013-01
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorazepam Small molecule 1 mg

Indications